Estracyt® in Advanced Prostatic Carcinoma: Case Report
- 1 January 1972
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 6 (1), 11-16
- https://doi.org/10.3109/00365597209132072
Abstract
A 75-year-old man with metastasising prostatic carcinoma was treated with Estracyt® (estradiol-3-N[bis-(2-chlorethyl)]-carbamate-17-dihydrogen phosphate). Histological and cytological examination showed complete regression of some lymph node metastases. Renographic and roentgen examinations revealed regression of other lymph node metastases. The patient felt better, his general condition improved and the indwelling catheter could be removed. Treatment was continued for 2 months during which the patient received a total of 9.5 g Estracyt® i.v. No side effects were observed.This publication has 3 references indexed in Scilit:
- Treatment of Advanced Prostatic Carcinoma with Estracyt: A Preliminary ReportScandinavian Journal of Urology and Nephrology, 1971
- Fermenthistochemische Untersuchungen zur Differenzierung benigner und maligner Wachstumsprozesse in der menschlichen ProstataUrologia Internationalis, 1970
- The Fine Structure and Histochemistry of Prostatic Glands in Relation to Sex HormonesInternational Review of Cytology, 1966